Werkgroep Cardiologische centra Nederland English

EMPEROR_HFrEF (Includerend)

A phase III randomized, double-blind study to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with Heart failure with reduced Ejection Fraction (HFrEF).

Middel
empagliflozin
Populatie
hartfalen
Fase
III
Jaar aanvang
2016
Meer informatie
ClinicalTrials.gov

Studiedirecteur

dr. R.G.E.J. Groutars (Cardioloog)
Amsterdam, OLVG